Key deals this week: Clorox, Spirit Airlines, GSK, PayPal, and more

Key deals this week: Clorox, Spirit Airlines, GSK, PayPal, and more
GSK announces $2.2 billion deal, targeting once-per-three-month food allergy drug
GSK to buy Rapt Therapeutics in deal valued at $2.2B
GSK turns to insider to be next CEO — and the stock rallies
UK's GSK announces $30 billion U.S. pharma investment amid Trump state visit - CNBC
GSK shares break six-session winning streak
114.63BUSD

See which Billionaires own this investment
Type
Common Stock
Exchange
NYSE
Currency Code
USD
Currency Name
US Dollar
Country Name
USA
Country ISO
US
ISIN
US37733W2044
CUSIP
37733W105
Sector
Healthcare
Industry
Drug Manufacturers - General
Fiscal Year End
December
IPO date
-
Updated At
-
PE Ratio
15.90
PEG Ratio
0.50
Book Value
5.40
Dividend Share
0.66
Dividend Yield
3.04%
Earnings Share
3.67
Wall Street Target Price
57.48
EPS Estimate Current Year
4.79
EPS Estimate Next Year
5.16
EPS Estimate Current Quarter
0.624
EPS Estimate Next Quarter
1.2082
Most Recent Quarter
-
Revenue TTM
32,667,000,832
Gross Profit TTM
23,719,999,488
EBITDA
11,335,000,064
Profit Margin
17.50%
Return On Assets TTM
9.79%
Return On Equity TTM
43.31%
Revenue Per Share TTM
16.128
Qtly Revenue Growth YOY
6.20%
Diluted Eps TTM
3.67
Qtly Earnings Growth YOY
54.70%
Trailing PE
15.90
Forward PE
22
Price Sales TTM
3.5696
Price Book MRQ
5.2237
Enterprise Value Revenue
3
Enterprise Value EBITDA
9
400.00
4.76%418.65
1.86%205.10
0.07%156.48
0.00%208.32
-1.93%120.73
-1.63%940.06
-1.59%239.00
-0.97%153.80
-0.83%50.00
-0.62%Curated watchlists where GSK is featured.